Shares of BioCryst Pharmaceuticals Inc. (BCRX) are down over 40% from their 52-week high of $11.31, recorded last June, and trade around $6.
This commercial-stage biotechnology company markets ORLADEYO, a plasma kallikrein inhibitor approved for the prophylaxis of hereditary angioedema (HAE) in patients aged 2 years and older, and a non-core product, RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com